Drug Profile
Research programme: osteoarthritis therapy - MIGENIX/University of California
Alternative Names: MITO 4042; MX 4042Latest Information Update: 17 Oct 2007
Price :
$50
*
At a glance
- Originator MIGENIX
- Developer MIGENIX; University of California, San Diego
- Class
- Mechanism of Action Mitochondrial protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 18 Apr 2006 This programme is still in active development
- 22 Sep 2004 Micrologix Biotech is now called MIGENIX
- 06 Sep 2004 MitoKor has been acquired and merged into Micrologix Biotech